United Therapeutics (UTHR) Current Assets (2009 - 2026)

United Therapeutics has disclosed Current Assets across 18 years of filings, most recently posting $2.9 billion for Q1 2026.

• Current Assets for Q1 2026 came in at $2.9 billion, down 27.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (down 27.1% YoY), and the FY2025 annual result was $3.7 billion, down 4.42% from the prior year.
• Current Assets came in at $2.9 billion for Q1 2026 at United Therapeutics, down from $3.7 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $4.0 billion in Q3 2024 to a low of $2.6 billion in Q1 2022.
• The 5-year median for Current Assets is $3.5 billion (2023), against an average of $3.4 billion.
• Across the five-year window, Current Assets jumped 45.48% in 2022 and declined 27.1% in 2026, its largest moves.
• United Therapeutics' Current Assets stood at $3.4 billion in 2022, then climbed by 5.05% to $3.6 billion in 2023, then gained by 9.09% to $3.9 billion in 2024, then declined by 4.42% to $3.7 billion in 2025, then dropped by 22.43% to $2.9 billion in 2026.
• The last three Current Assets figures came in at $2.9 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.